Is CervoMed Inc. (CRVO) a Buy, Sell, or Hold?
CervoMed Inc.
NASDAQ:CRVO
$3.08 USD
-$0.23 (-6.95%)
- Volume
- 892.96K
- Average Volume
- 5.6M
- Market Capitalization
- $28.52M
- P/E Ratio
- -0.94
- Dividend Yield
- 0.00%
- Price Target
- $9.00
- Year High
- $13.13
- Year Low
- $2.13
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.36
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | John J. Alam |
| Industry | Specialty Business Services |
| Sector | Industrials |
| Current Symbol | CRVO |
| CUSIP | 15713L109 |
| CIK | 0001053691 |
| Web | https://www.cervomed.com |
| Phone | 617-744-4400 |
| Currency | USD |
| Employees | 15 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 3.36 |
| Quick Ratio | 3.36 |
| Cash Ratio | 1.77 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 88.41 |
| Cash Flow | -2.98 |
| Price / Cash Flow | -1.03 |
| Price / Book | 2.69 |
Price Target and Rating
| Average Stock Price Forecast | $9.00 |
| High Stock Price Forecast | $9.00 |
| Low Stock Price Forecast | $9.00 |
| Forecast Upside/Downside | -65.78% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 7 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-2.98 |
| Trailing P/E Ratio | -0.94 |
| PEG Ratio | 0.02 |
| P/E Growth | 0.02 |
| Net Income | $-26.97M |
| Net Margin | -9311.65% |
| Pretax Margin | -9311.65% |
| Return on Equity | -136.08% |
| Return on Assets | -198.75% |
Financials Score
| AltmanZ Score | -11.68 |
| Piotroski Score | 2.00 |
| Working Capital | 10.62M |
| Total Assets | 15.11M |
| Ebit | -30.04M |
| Market Cap | 28.52M |
| Total Liabilities | 4.5M |
Poll Results
About CervoMed Inc. (NASDAQ:CRVO) Stock
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts. ...
2026-07-14 07:30:00
BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
2026-07-09 07:30:00
Interim biomarker data accepted for presentation at the 19 th Clinical Trials on Alzheimer's Disease (CTAD) conference
2026-07-06 07:30:00
Latest findings on neflamapimod to be featured in presentations demonstrating its impact on dementia with Lewy bodies (DLB) disease progression, biomarkers of neurodegeneration, and basal forebrain atrophy, as well as optimal dosing strategies
2026-06-22 16:05:00
BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 2,500,000 shares of common stock at a purchase price of $4.00 per share.
2026-06-18 12:35:00
BOSTON, June 18, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that it has entered into definitive agreements for the purchase and sale of 2,500,000 shares of common stock at a purchase price of $4.00 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about June 22, 2026, subject to the satisfaction of customary closing conditions.
2026-06-18 07:00:00
BOSTON, June 18, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) related to a new patent protecting the Company's use of its drug candidate, neflamapimod, for the treatment of dementia with Lewy bodies (DLB) in patients with no substantial Alzheimer's disease-like tau pathology, also known as “pure DLB”. The patent will cover the treatment of DLB without substantial tau pathology, which can be characterized by plasma levels of pTau or brain imaging, and is expected to provide intellectual property protection into 2042 and potentially longer with patent term extension.
CervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
2026-06-12 07:30:00
BOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that Company management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit, being held virtually on Monday, June 15, 2026.
2026-06-10 07:30:00
Additional funding will extend anticipated runway into second quarter of 2027 Strategic priority is to establish a partnership to advance neflamapimod into Phase 3 in dementia with Lewy bodies Anticipated pipeline milestones over next six months include obtaining 24-week biomarker and clinical data from Phase 2a trial evaluating neflamapimod in nonfluent variant primary progressive aphasia and initiation of EXPERTS-ALS Phase 2a trial Financing includes substantial participation from insiders and leading institutional healthcare investors BOSTON, June 10, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that it has entered into a definitive securities purchase agreement for a private placement, from which the Company anticipates upfront gross proceeds of approximately $10.5 million, before deducting offering-related fees and expenses. The private placement financing was led by leading institutional healthcare investors, and was supported by insiders, including Joshua S.
Frequently Asked Questions
-
What is the current CervoMed Inc. (CRVO) stock price?
-
CervoMed Inc.(NASDAQ:CRVO) stock price is $3.08 in the last trading session. During the trading session, CRVO stock reached the peak price of $13.13 while $2.13 was the lowest point it dropped to. The percentage change in CRVO stock occurred in the recent session was --6.95% while the dollar amount for the price change in CRVO stock was -$-0.23.
-
CRVO's industry and sector of operation?
-
The NASDAQ listed CRVO is part of Specialty Business Services industry that operates in the broader Industrials sector.
-
Who are the executives of CRVO?
-
Mark A. De Rosch | Executive Vice President of Regulatory, Government Affairs & Program Management
Kelly Blackburn | Executive Vice President of Clinical Development
John J. Alam | Co-Founder, Chief Executive Officer, President & Director
Marinus Verwijs | Executive Vice President of Technical Operations
Claudia Ordonez | Senior Vice President of Medical Science -
How many employees does CRVO have?
-
Number of CRVO employees currently stands at 15. CRVO operates from 20 Park Plaza, Boston, MA 02116, US.
-
Link for CRVO official website?
-
Official Website of CRVO is: https://www.cervomed.com
-
How do I contact CRVO?
-
CRVO could be contacted at phone #617-744-4400 and can also be accessed through its website. CRVO operates from 20 Park Plaza, Boston, MA 02116, US.
-
How many shares of CRVO are traded daily?
-
The average number of CRVO shares traded daily for last 3 months was 5.6M.
-
What is the market cap of CRVO currently?
-
The market value of CRVO currently stands at $28.52M with its latest stock price at $3.08